

1 SUBMITTED 1 FEB 22  
2 REVISIONS REQ. 19 MAY & 8 AUG 22; REVISIONS RECD. 10 JUN & 17 AUG 22  
3 ACCEPTED 27 AUG 22  
4 **ONLINE-FIRST: FEBRUARY 2023**  
5 DOI: <https://doi.org/10.18295/squmj.1.2023.006>  
6

7 **Comparison of Short-Course versus Conventional Antimicrobial Duration**  
8 **in Mild and Moderate Complicated Intra-Abdominal Infections**

9 *A randomised controlled trial*

10 **P. Vinodhini,<sup>1</sup> Sathasivam Sureshkumar,<sup>1</sup> Balakrishnan Gurushankari,<sup>1</sup>**  
11 **Thulasingham Mahalakshmy,<sup>2</sup> \*Vikram Kate<sup>1</sup>**

12  
13 *Departments of <sup>1</sup>Surgery & Preventive and <sup>2</sup>Social Medicine, Jawaharlal Institute of*  
14 *Postgraduate Medical Education and Research, Pondicherry, India*

15 *\*Corresponding Author's e-mail: [drvikramkate@gmail.com](mailto:drvikramkate@gmail.com)*  
16

17 **Abstract**

18 **Objectives:** Studies have shown the feasibility of short-course antimicrobials in complicated  
19 intra-abdominal infection (CIAI) following source control procedure (SCP). This study was  
20 carried out to compare post-operative complication rates in short-course (5 days) and  
21 conventional (7–10 days) duration groups after antimicrobial therapy. **Methods:** This was a  
22 single-centre, open-labelled, randomised control trial conducted from July 2017 to December  
23 2019 upon patients with CIAI. Patients who were haemodynamically unstable, pregnant and  
24 had non-perforated, non-gangrenous appendicitis or cholecystitis were excluded. Primary  
25 endpoints were surgical site infection (SSI), recurrent intra-abdominal infection (IAI) and  
26 mortality. Secondary endpoints included time till occurrence of composite primary outcomes,  
27 duration of antimicrobial therapy, the length of hospital stays, antimicrobial-free interval,  
28 hospital-free days at 30 days' interval and the presence of extra-abdominal infections.

29 **Results:** Overall, 140 patients were included whose demographic and clinico-pathological  
30 details were comparable in both groups. There was no difference in SSI (37% vs. 35.6%) and  
31 recurrent IAI (5.7% vs. 2.8%;  $P = 0.76$ ), and no mortality was observed in either groups. The  
32 composite primary outcome (37% vs. 35.7%) was also similar in both groups. Secondary  
33 outcomes included the duration of antimicrobial therapy (5 vs. 8 days;  $P < 0.001$ ) and length

34 of hospitalisation (5 days vs. 7 days;  $P = 0.014$ ) were significant. Times till occurrence of SSI  
35 and recurrent IAI, incidence of extra-abdominal infection and resistant pathogens were  
36 comparable. **Conclusion:** Short-course antimicrobial therapy for 5 days following SCP for  
37 mild and moderate CIAI was comparable to conventional duration antimicrobial therapy,  
38 indicating similar efficacy.

39 **Keywords:** Abdominal Abscess; Antibiotic Prophylaxis; Antimicrobial Stewardship;  
40 Appendicitis, Perforated; Drug Resistance, Microbial; Intra-abdominal Infection; Peritonitis;  
41 Surgical Wound Infection.

42

### 43 **Advances in Knowledge**

- 44 • The use of short-course antimicrobials in complicated intra-abdominal infections is safe  
45 and efficacious.
- 46 • Short-course antimicrobial therapy leads to a reduced length of hospital stay.
- 47 • Short-course antimicrobial therapy has a comparable post-operative outcome to  
48 conventional antimicrobial therapy.

49

### 50 **Applications to Patient Care**

- 51 • Short-course antimicrobials help reduce the development of antibiotic resistances, which  
52 is considered a major concern across the globe.
- 53 • It also helps in early discharge of patients and for maintaining a better cost-benefit ratio in  
54 the hospitals.

55

### 56 **Introduction**

57 Complicated intra-abdominal infection (CIAI) is one of the most frequent cases encountered  
58 by a surgeon in an emergency scenario. CIAI is usually defined as abscess formation or  
59 peritonitis beyond the origin of the perforation of a hollow viscus in the peritoneal cavity,  
60 which requires an invasive procedure for source control.<sup>1-3</sup> The three pillars of management  
61 are fluid resuscitation, source control procedure (SCP) and the usage of antibiotics to  
62 eliminate residual organisms.<sup>1-3</sup> Patients undergoing major abdominal surgery, in which  
63 infective post-operative complications are anticipated, require peri-operative antibiotic cover.  
64 This necessity is more pronounced in the subset of patients who undergo emergency  
65 abdominal surgery, especially when the patient has associated abdominal or generalised  
66 sepsis. Traditionally, in such cases, antibiotic coverage is stopped two days after the

67 resolution of systemic inflammatory response syndrome as documented by the normalisation  
68 of total leucocyte counts and resolution of fever.<sup>2</sup>

69

70 Conventionally, the recommended duration of the use of antibiotics in these conditions is  
71 between 10 and 14 days.<sup>3,4</sup> However, recent evidences indicate that not all post-operative  
72 febrile episodes are due to active abdominal infection.<sup>2-5</sup> The Surviving Sepsis Campaign  
73 guidelines recommend that relevant cultures should be obtained and antibiotic therapy should  
74 be modified accordingly.<sup>6</sup> Recent reports imply that the duration of antibiotics can be  
75 shortened after a proper SCP is followed to control the sepsis and that there is no need for  
76 antibiotics to be continued for an extended period after an SCP.<sup>3</sup> Studies have shown the  
77 utility and efficacy of short-course antibiotic usage after SCP in complicated IAIs both in  
78 open and laparoscopic procedures.<sup>2-5</sup> However, despite this, many surgeons are still  
79 apprehensive in implementing the same. This fear is mostly attributed to the possibility of  
80 post-operative IAIs developing in patients, as well as multiple nosocomial infections that  
81 patients are exposed to in the hospital.<sup>7</sup> However, the decrease in the duration of antibiotics  
82 helps in shortening the length of hospital stay, and it has been shown to have comparable  
83 results in terms of post-operative complications.<sup>6</sup>

84

85 Management of a complicated IAI requires vigilant and timely intervention in order to  
86 contain the sepsis, which includes fluid and electrolyte correction, an effective SCP and  
87 judicious use of antimicrobials. All these three measures should be carried out expediently in  
88 order to achieve a good outcome. The duration of antibiotics is crucial as undertreatment and  
89 overtreatment can be detrimental to the patient. However, the optimum duration for the  
90 course of antibiotics is still debatable. Recent reports have shown that the use of a short  
91 course of antimicrobials after an effective SCP may be satisfactory for the control of  
92 infection, the rationale being that the SCP helps in eliminating a major portion of the sepsis,  
93 and thereafter, since the load of bacteria is expected to be largely reduced, the duration of  
94 antimicrobials can be safely truncated.<sup>8</sup>

95

96 Though studies have shown that short-course antimicrobial therapy is safe and effective  
97 compared with conventional long-course therapy, it is to be noted that a majority of these  
98 studies were carried out in Western countries, where the antibiotic usage is well regulated and  
99 antibiotic resistance is low. However, in the developing countries, with varying patient  
100 profile, poor nutritional status, delayed presentation, diverse aetiology of intra-abdominal

101 infection, unrestricted antimicrobial usage with higher resistance pattern, etc., the efficacy of  
102 short-course antimicrobial therapy needs to be studied to assess their effectiveness in these  
103 populations. Hence, this study was carried out to compare the rates of post-operative  
104 complications in patients with complicated IAIs after conventional duration and short-course  
105 antimicrobial therapy.

106

## 107 **Methods**

108 This study was a randomised controlled trial, which was single-centred, non-inferior and  
109 open-labelled, conducted in the surgery department in a tertiary referral hospital during the  
110 period from July 2017 to December 2019. The study was recorded at [www.ctri.gov.in](http://www.ctri.gov.in), and a  
111 registration number was provided. This work has been reported in accordance with the  
112 Consolidated Standards of Reporting Trials (CONSORT) guidelines.

113

114 Patients aged  $\geq 18$  years who presented to the emergency surgical unit and were diagnosed  
115 with complicated IAIs such as perforated/gangrenous appendicitis/cholecystitis, bowel  
116 gangrene/perforation and gastric/duodenal perforation with peritonitis were enrolled and  
117 assessed for eligibility. The diagnosis was confirmed by clinical examination and relevant  
118 laboratory and radiological investigations. Patients who were haemodynamically unstable,  
119 who were pregnant and who had non-perforated, non-gangrenous appendicitis or  
120 cholecystitis, infected necrotising pancreatitis, primary spontaneous bacterial peritonitis and  
121 infection associated with indwelling peritoneal dialysis catheter were excluded.

122

123 Patients who received antimicrobial therapy for either 5 days or of a conventional duration of  
124 7–10 days were randomly assigned in a 1:1 ratio. A computer programme was used for block  
125 randomisation with block sizes of 4 and 6 selected randomly. The technique called ‘serially  
126 numbered opaque sealed envelope’ (SNOSE) was used for concealment during allocation. A  
127 person independent of the investigators had prepared these sealed envelopes. The nurse  
128 opened the envelope at the time of decision of surgery, and group allocation was done.

129

130 Before the operation, all patients were stabilised by fluid resuscitation according to  
131 conventional guidelines and were started on intravenous (IV) empirical antibiotics.<sup>9</sup> Standard  
132 preoperative care was provided as per the routine protocol. Patients were admitted in the  
133 emergency surgical ward, and laboratory investigations and imaging including contrast  
134 enhanced computed tomography were carried out for the diagnosis. Placement of a

135 nasogastric tube at admission, urinary catheterisation and administration of crystalloids for  
136 fluid replacement were done. Patients received IV empirical antibiotic therapy with  
137 ceftriaxone and metronidazole or piperacillin–tazobactam depending on the possible grade of  
138 infection and IV acid reducing therapy with pantoprazole.<sup>9,10</sup>

139

140 All patients underwent open laparotomy and received standard SCP as per the primary  
141 diagnosis, which included omental patch closure for gastric or duodenal perforation, primary  
142 resection anastomosis or stoma for bowel gangrene, appendectomy and peritoneal lavage for  
143 gangrenous or perforated appendix, etc. Intraoperative fluid or specimen was sent for aerobic  
144 culture. Patients in the short-course group and in the conventional duration group received  
145 antimicrobial therapy for 5 days and for 7–10 days, respectively.<sup>2</sup> In both the groups, the  
146 antibiotics that were given were ceftriaxone with metronidazole or piperacillin–tazobactam  
147 based on a mild or moderate infection, which was diagnosed taking into account the total and  
148 differential leucocyte count, fever, respiratory rate and the possible organ involved based on  
149 the radiological investigation. These antibiotics were administered based on the antibiotic  
150 guidelines of the authors' institute, which is based not only on the sensitivity and resistance  
151 pattern of their hospital but also based on the standard guidelines of the international  
152 society.<sup>3,10</sup> In cases where the intraoperative pus/fluid culture showed a resistance pattern to  
153 the ongoing antibiotics, a sensitive antibiotic was given as per the culture and sensitivity  
154 report within 48 hours of starting the initial antibiotics. Subsequent occurrence of recurrent  
155 intra-abdominal infection and surgical site infection (SSI) were treated as per the standard  
156 protocol and with antibiotics based on the culture report.

157

158 Patients were monitored till the time of discharge for the presence of SSI, recurrent IAI or  
159 death due to any cause. In case of development of SSI or recurrent abdominal infection, a  
160 wound swab or percutaneously/surgically drained fluid was sent for culture and sensitivity.  
161 Patients were followed up till the time of discharge and on days 15 and 30 post the operation  
162 for occurrence of any of the primary outcomes and complications, for re-admission and for  
163 mortality.

164

165 The primary endpoints in the two groups were development of SSI, recurrent IAI and  
166 mortality. The primary outcome was assessed as a composite endpoint comprising any one,  
167 two or three of the primary endpoints. The secondary outcome included the time of the  
168 occurrence of composite primary outcomes, duration of antimicrobial therapy, the length of

169 hospital stays, antimicrobial-free interval, hospital-free days at 30 days' interval and the  
170 presence of extra-abdominal infections.

171

172 The composite primary outcomes were used for power analysis. The sample size was  
173 calculated using nMaster software Version 2.0. Assuming the proportion of composite  
174 primary outcome in the conventional duration group to be 30–40%<sup>2</sup> and a non-inferiority  
175 margin of 10%, the sample size was calculated as 70 in each arm (total = 14), with a power of  
176 80%, an alpha error of 5% and estimated loss to follow up of 10%.

177

178 Data were collected as per the specified pro-forma prepared by the investigators. Various  
179 demographic variables such as age, gender, address, organ of infection and SCP were  
180 collected and analysed.

181

182 Statistical analysis was done using SPSS Version 20.0. Continuous variables such as time till  
183 the occurrence of composite primary outcome and duration of antimicrobial therapy were  
184 expressed as mean (SD) or median (IQR) depending upon the normality of distribution.  
185 Categorical variables such as parameters of primary outcomes were expressed as proportions.  
186 The chi-square test was used to compare the proportions of primary endpoints and composite  
187 primary outcome in the two groups. Secondary outcomes such as the time till the occurrence  
188 of primary endpoints and composite primary outcomes, duration of antimicrobial therapy, the  
189 length of hospital stay, antimicrobial-free interval and hospital-free days at 30 days' interval  
190 were compared using the Mann-Whitney U test. Fisher's test was used to compare the  
191 incidence of extra-abdominal infections and organisms of aerobic infection in the two groups.  
192 All results were interpreted as intention-to-treat analysis. A 'P' value below 0.05 was  
193 considered as statistically significant.

194 The study was approved by the Institute Ethics Committee (IEC), and written informed  
195 consent was taken from all the participants.

196

## 197 **Results**

198 A total of 164 patients with complicated IAI were assessed for eligibility from July 2017 to  
199 May 2019. A total of 24 patients were excluded [Figure 1]. The remaining 140 patients were  
200 randomised, with 70 in the short-course group and 70 in the conventional duration group.

201 There was no loss to follow up. The two groups were comparable in terms of all demographic  
202 and clinico-pathological characteristics [Table 1].

203

204 The incidence of superficial incisional SSI was 31.4% and 32.8%, deep incisional SSI was  
205 2.8% and 1.4% and organ space infection was 2.8% and 1.4% in the short-course and the  
206 conventional duration antimicrobial therapy groups, respectively ( $P = 0.764$ ) [Table 2]. Four  
207 and two patients developed recurrent IAI in the short-course group and in the conventional  
208 duration group, respectively, and two and one patients developed deep organ space infection  
209 in the short-course group and the conventional duration group, respectively. Except one  
210 patient in the short-course group who had post-operative leak after the initial adequate source  
211 control by omental patch closure for duodenal perforation (upper GI), which resulted in  
212 recurrent IAI, the rest of the patients in both the groups had a small bowel or appendix (lower  
213 GI) aetiology as a source of CIAI. The incidence of recurrent IAI was similar at 5.7% and  
214 2.8% in the short-course and conventional duration antimicrobial therapy groups,  
215 respectively. There was no mortality in both the groups. The composite primary outcome was  
216 37% and 35.7% in the short-course and conventional duration groups, which was also similar.

217

218 There was a significant reduction in the length of hospital stay by 3 days in the short-course  
219 and conventional duration antimicrobial therapy groups ( $P < 0.001$ ) [Table 3]. There was a  
220 significant reduction in the duration of antimicrobial therapy by 2 days in the short-course  
221 and conventional duration antimicrobial therapy groups ( $P < 0.001$ ). The time till the  
222 occurrence of SSI was  $3.8 \pm 0.7$  and  $4.2 \pm 1.2$  days ( $P = 0.77$ ) and recurrent IAI was  
223  $7 \pm 1.8$  and  $5.3 \pm 0.5$  days ( $P = 0.195$ ) in the short-duration and conventional duration  
224 groups, respectively. The time till the occurrence of composite primary outcome was  
225  $4.1 \pm 1.6$  and  $4.5 \pm 1.3$  days in both the groups, which was similar ( $P = 0.256$ ) [Table 4].  
226 The incidence of extra-abdominal infections such as urinary tract infection (2.8% vs. 2.8%),  
227 bloodstream infection (4.2% vs. 2.8%), pulmonary infection (4.2% vs. 5.6%) and vascular  
228 catheter-associated infection (1.4% vs. 0) were similar in the two groups ( $P = 0.582$ ).

229

230 *Escherichia coli* (55.1% vs. 49.7%) was the most common organism isolated from the culture  
231 specimen followed by *Enterococcus* (2.9% vs. 7.6%), *Klebsiella* (2.9% vs. 2.5%),  
232 *Pseudomonas* (2.9% vs. 2.5%) and *Acinetobacter* (2.9% vs. 2.5%) in the short-course and  
233 conventional duration groups, respectively [Table 5]. Nearly 33.3% of the study group and  
234 35.2% of the conventional duration group showed poly-microbial growth.

235

236 Based on the intraoperative culture and sensitivity report, 9.2% of the study population  
237 required a change of antibiotics due to resistance of the primary antibiotics that were given  
238 perioperatively. Culture-sensitive antibiotics such as third-generation cephalosporins with  
239 metronidazole, piperacillin–tazobactam, meropenem or imipenem–cilastatin with  
240 metronidazole were used for SSI and recurrent intra-abdominal infection in the study  
241 population.

242

## 243 **Discussion**

244 This study showed that short-course antimicrobial therapy for 5 days following SCP for  
245 complicated IAI had similar outcomes to antimicrobial therapy for a conventional duration. A  
246 significant reduction in the length of hospitalisation in patients undergoing short-course  
247 antimicrobial therapy was also observed. The times till the occurrence of SSI and recurrent  
248 IAI were comparable between the two groups. Also, the times till the occurrence of  
249 composite primary outcome were similar among the two groups. The incidences of extra-  
250 abdominal infections such as urinary tract infection, bloodstream infection, pulmonary  
251 infection and vascular catheter-associated infection were similar in the two groups. *E. coli*  
252 was the most common organism isolated from the culture specimens in both the groups,  
253 followed by *Enterococcus*, *Klebsiella*, *Pseudomonas* and *Acinetobacter*.

254

255 Only a few reports have been published on the use of antimicrobials for a shorter duration in  
256 complicated IAI.<sup>2</sup> Although recent guidelines and a few studies in this aspect have shown a  
257 similar outcome as short-course antimicrobial therapy, surgeons are still apprehensive in  
258 implementing the same in clinical practice, due to the life-threatening consequences of  
259 potential undertreatment.<sup>3</sup> In this study, the primary outcomes such as SSIs and recurrent  
260 IAIs were comparable in the short-course and conventional duration antimicrobial groups.

261

262 In this study, appendicular perforation occurred in the maximum number of cases. Though a  
263 significant number of patients had small and large bowel perforations, they could not be  
264 included in the study as they were haemodynamically unstable and required inotropes support  
265 at the time of presentation. This was consistent with the study conducted by Lopez et al., in  
266 which appendicular perforation was the most common cause of peritonitis.<sup>11</sup> In this study, the  
267 most common organism isolated was *E. coli*, which was similar to a report from San Diego.<sup>2</sup>  
268 In this study, after *E. coli*, *Enterococcus* was the next organism isolated in a very small  
269 number of cases while the cultures of many patients showed more than one aerobic organism



270 growing in them. In a small subset of patients, anaerobic organisms such as *Bacteroides*  
271 *fragilis* were found growing in their culture. As per the Surgical Infection Society-Infectious  
272 Diseases Society of America (SIS-IDSA) guidelines, third-generation cephalosporins with  
273 metronidazole are recommended in patients with complicated IAIs who are at low risk, while  
274 in patients at high risk, piperacillin-tazobactam, meropenem or imipenem–cilastatin with  
275 metronidazole can be used.<sup>12</sup> Addition of metronidazole to the antibiotic therapy has been  
276 shown to reduce the post-operative complications as *B. fragilis* are obligate anaerobes in the  
277 distal small bowel and large bowel.<sup>13</sup> In this study, third-generation cephalosporins and  
278 metronidazole were given to most patients, while patients at high risk received piperacillin-  
279 tazobactam. Antimicrobials and its use in the complicated IAI are based on the susceptibility  
280 of the organisms.<sup>14</sup> The antibiotics in this study were used according to the hospital  
281 guidelines and policy.

282

283 Similar to this study, another report administered  $4 \pm 1$  days of antibiotics in the short-course  
284 group, and the conventional duration group received antibiotics till the fever resolved and  
285 white cell counts were elevated. Schein et al. also reported the use of 3–5 days of antibiotics  
286 in patients with complicated IAI following SCP.<sup>15</sup> In this study, the short-course group and  
287 the conventional duration group received 5 and 7–10 days of antibiotics, respectively. In both  
288 the groups, a few patients received antibiotics for a longer time than the stipulated duration,  
289 when they had organ space infection, recurrent IAI and extra abdominal infection. In a study  
290 from the United States and Canada, 10% of the patients had received antibiotics for extra  
291 duration owing to the occurrence of wound infections and extra-abdominal infection.<sup>2</sup> In this  
292 study, in the short-course group, 4 patients had re-exploration and 2 patients had organ space  
293 infection, which required a longer duration of antibiotics. Among the 4 patients, in one of the  
294 patients a post-operative leak occurred after the initial adequate source control by omental  
295 patch closure, which resulted in recurrent IAI. Two patients had anastomotic leak, which  
296 required re-exploration, and one other patient had an iatrogenic perforation, which was  
297 detected in the post-operative period. Though the majority of the studies advocate short-  
298 course antimicrobial therapy after adequate source control for mild to moderate IAI, a longer  
299 duration of therapy may be required for patients with severe IAI and showing features of  
300 severe sepsis. These patients may have an unpredictable clinical course and require a more  
301 complex and individualised approach for the diagnosis of ongoing sepsis, the reason for  
302 antimicrobial failure and continuous monitoring of inflammatory markers.<sup>16</sup> In this study,  
303 patients in the short-course and the conventional duration groups developed extra-abdominal

304 infection at the rate of 12.6% and 11.2%, respectively. Pulmonary infection accounted for  
305 majority of the infections.

306

307 In the RCT by Sawyer et al., the recurrent intra-abdominal infection rate was considerably  
308 high: 36 (13.8%) in the control group vs. 40 (15.6%) in the experimental group with  $P =$   
309 0.67, compared with the lesser recurrent intra-abdominal infection rate in this study: 4 (5.7%)  
310 in the short-course group vs. 2 (2.8%) in the conventional duration group. Considering the  
311 lesser number of events in both the groups in this study, the difference was not observed. In  
312 this study, the short-course group had 40.2% of infectious complications and the conventional  
313 duration group had 38.4% out of which SSIs accounted for a majority of cases, superficial  
314 incisional SSI being the most common. There was no mortality in both the groups. In another  
315 report, the rate of infectious complications were more than 20% in both the groups; however,  
316 the majority of the cases were recurrent IAIs.<sup>2</sup> There were two deaths in the study group and  
317 three deaths in the experimental group. Antibiotics such as ertapenem had been given for  
318 only 3 days to patients with mild to moderate IAIs with a successful outcome.<sup>17</sup>

319

320 The times taken till the occurrence of SSIs and recurrent IAIs were similar in the two groups.  
321 The time till the occurrence of the composite primary outcome was 4.1 days in the short-  
322 course group. This led to early detection and timely intervention, thus avoiding the need for  
323 readmissions.

324

325 In this study, the antimicrobial-free days at 30 days' interval was 3 days less in the short-  
326 course group with comparable post-operative complications. The hospitalisation duration  
327 after the index procedure was 2 days less in the short-course group and was cost-effective.

328

329 There were certain limitations in our study. In this study, in the majority of patients the  
330 source of IAI was from the appendix or the small bowel with mild to moderate severity.  
331 Severe IAI and colon as a source were found only in a limited number of patients. Hence, the  
332 results of this study are predominantly applicable to mild to moderate IAI. The SSI rate in  
333 this study is high compared with the published literature from the Western population. As the  
334 authors' hospital is a public sector institute in a developing country, the patient population is  
335 usually from a low socioeconomic status, with poor knowledge of personal hygiene and self-  
336 care. The patients also mostly present late following the onset of symptoms, which could  
337 possibly lead to higher incidence of SSI. Previous published studies by the authors' institute

338 on SSI have also shown a similar rate of SSI, indicating the possible role of patient  
339 population in the higher rate of SSI.<sup>18,19</sup>

340

### 341 **Conclusion**

342 This study shows that short-course antimicrobial therapy when compared with conventional  
343 duration therapy has comparable incidences of SSI and recurrent IAI in patients with mild  
344 and moderate complicated IAI. The time till the occurrence of composite primary outcomes  
345 and the presence of extra-abdominal infections were similar in both the groups. There was a  
346 significant reduction in the duration of antimicrobial therapy and the length of hospital stays.  
347 Future studies are recommended to include critically ill patients to assess the efficacy of  
348 short-term antimicrobial therapy following SCP in severe CIAI.

349

### 350 **Declaration**

351 Parts of this manuscript results have been published as an abstract at the *61st Annual Meeting*  
352 *of the Society for Surgery of the Alimentary Tract, USA (2020)* under the title ‘Comparison of  
353 short course antimicrobial therapy vs. Conventional antimicrobial therapy in patients with  
354 complicated intra-abdominal infections: A randomised controlled trial.’ The same is available  
355 at <https://meetings.ssat.com/abstracts/2020/180.cgi>.

356

### 357 **Acknowledgements**

358 The authors would like to thank Dr Rohith Gorrepati and Dr Evangeline Mary Kiruba  
359 Samuel, Senior Residents, Department of Surgery, and Dr Arivarasan, Former Junior  
360 Resident, Department of Preventive and Social Medicine, Jawaharlal Institute of Post  
361 Graduate Medical Education and Research (JIPMER), Pondicherry, India, for their support in  
362 conducting the study and for helping in the statistical analysis.

363

### 364 **Authors' Contribution**

365 PV was involved in the data collection, formal analysis, investigation and writing of the  
366 original draft; SS in the conceptualisation, supervision and review and editing; BG in the  
367 methodology, formal analysis, writing of the original draft and revision of the manuscript;  
368 TM in the formal analysis, supervision and review and editing and VK in the  
369 conceptualisation, formal analysis, supervision, validation and review and editing. All authors  
370 approved the final version of this manuscript.

371

372 **Conflict of Interest**

373 The authors declare no conflict of interest.

374

375 **Funding**

376 No funding was received for this study.

377

378 **References**

379 1. Sartelli M. A focus on intra-abdominal infections. *World J Emerg Surg* 2010; 5:9. doi:  
380 10.1186/1749-7922-5-9.

381 2. Sawyer RG, Claridge J A, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of  
382 short course antimicrobial therapy for intra-abdominal infections. *N Engl J Med* 2015;  
383 372:1996–2005. doi: 10.1056/NEJMoa1411162.

384 3. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al.  
385 Diagnosis and management of complicated intra-abdominal infection in adults and children:  
386 Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.  
387 *Clin Infect Dis* 2010; 50:133–64.

388 4. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines  
389 for the selection of anti-infective agents for complicated intra-abdominal infections. *Clin Infect*  
390 *Dis* 2003; 37:997–1005. doi: 10.1086/378702.

391 5. Van Rossem CC, Schreinemacher MH, van Geloven AA, Bemelman WA. Snapshot  
392 Appendicitis Collaborative Study Group: Antibiotic duration after laparoscopic appendectomy  
393 for acute complicated appendicitis. *JAMA Surg* 2016; 151:323–9. doi:  
394 10.1001/jamasurg.2015.4236. PMID: 26580850.

395 6. The Surviving Sepsis Campaign Bundle. *Intensive Care Med* 2018; 44. doi: 10.1007/s00134-  
396 018-5085-0.

397 7. Inui T, Haridas M, Claridge JA, Malangoni MA. Mortality for intra-abdominal infection is  
398 associated with intrinsic risk factors rather than the source of infection. *Surgery* 2009; 146:654–  
399 61. doi: 10.1016/j.surg.2009.06.051.

400 8. M F Jiminez, Marshal J C. Source control in the management of sepsis. *Intensive Care Med*  
401 2001; 27:S49–62. doi: 10.1007/pl00003797.

402 9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis  
403 Campaign: International guidelines for management of severe sepsis and septic shock.  
404 *Intensive Care Med* 2008; 34:17–60. doi: 10.1007/s00134-007-0934-2.

405 10. Nathens AB, Rotstein OD. Therapeutic options in peritonitis. *Surg Clin North Am* 1994;  
406 74:677–692.

407 11. Lopez N, Kobayashi L, Coimbra Raul. A comprehensive review of abdominal infections.  
408 *World J Emerg Surg* 2011; 6:7. doi: 10.1186/1749-7922-6-7.

409 12. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, et al. The Surgical  
410 Infection Society guidelines on antimicrobial therapy for intraabdominal infections: An  
411 executive summary. *Surg Infect (Larchmt)* 2002; 3:161–73. doi:  
412 10.1089/109629602761624171.

413 13. Jamalov FH, Agayev RM, Achundov IT, Huseynov SG, Jamalova TP. Antibacterial  
414 prophylaxis in emergency surgery of abdominal infection. *Euroasian J Hepatogastroenterol*  
415 2018; 8:116–20. doi: 10.5005/jp-journals-10018-1276.

416 14. Haddad N, Kanj SS, Awad LS, Abdallah DI, Moghnieh RA. The 2018 Lebanese Society  
417 of Infectious Diseases and Clinical Microbiology Guidelines for the use of antimicrobial  
418 therapy in complicated intra-abdominal infections in the era of antimicrobial resistance. *BMC*  
419 *Infect Dis* 2019; 19:293.

420 15. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal  
421 surgery: A prospective study. *Br J Surg* 1994; 81:989–91. doi: 10.1002/bjs.1800810720.


422 16. Sartelli M, Catena F, Ansaloni L, Coccolini F, Di Saverio S, Griffiths EA. Duration of  
423 antimicrobial therapy in treating complicated intra-abdominal infections: A comprehensive  
424 review. *Surg Infect (Larchmt)* 2016; 17 :9–12. doi: 10.1089/sur.2015.130. Epub 2015 Oct 15.  
425 PMID: 26468904.

426 17. Basoli A, Chirletti P, Cirino E, D'Ovidio NG, Doglietto GB, Giglio D, et al. A prospective,  
427 double-blind, multicenter, randomized trial comparing ertapenem 3 vs.  $\geq 5$  Days in community-  
428 acquired intra-abdominal infection. *J Gastrointest Surg* 2008; 12:592–600. doi:  
429 10.1007/s11605-007-0277-x.

430 18. Pranavi AR, Sureshkumar S, Mahalakshmy T, Kundra P, Kate V. Adapted ERAS pathway  
431 versus standard care in patients undergoing emergency surgery for perforation peritonitis: A  
432 randomized controlled trial. *J Gastrointest Surg* 2022; 26:39–49. doi: 10.1007/s11605-021-  
433 05184-x. PMID: 34755312.

434 19. Mayank M, Mohsina S, Sureshkumar S, Kundra P, Vikram Kate. Effect of perioperative  
435 high oxygen concentration on postoperative SSI in elective colorectal surgery: A randomized  
436 controlled trial. *J Gastrointest Surg* 2019; 23:145–152. doi: 10.1007/s11605-018-3996-2. Epub  
437 2018 Oct 8. PMID: 30298417.

438



439 **Figure 1:** CONSORT diagram for the study

440

441

442

443 **Table 1:** Baseline demographic and clinical characteristics in the short-course and  
 444 conventional duration groups

Variables	Short-Course Group (n = 70) (n [%])	Conventional Duration Group (n = 70) (n [%])	P Value
Age-yrs (mean $\pm$ SD)	40 $\pm$ 15.5	43 $\pm$ 15.8	0.11
Male patients	54 (77.1)	51 (72.8)	0.55
<i>Organ of origin</i>			
Appendix	32 (45.7)	34 (48.5)	
Small bowel	23 (32.8)	27 (38.5)	
Stomach	11 (15.7)	6 (8)	0.465
Large bowel	3 (4.2)	2 (2.6)	
Gall bladder	1 (1.4)	1 (1.4)	
<i>SCP<sup>l</sup></i>			
Appendectomy	32 (45.7)	34 (48.5)	
Omental patch closure	21 (30)	18 (25)	
Resection and anastomosis	8 (11)	7(10)	0.764
Resection and stoma	8 (11)	10(15)	
Pigtail	1 (1)	1 (1)	

445 *I-source control procedure.*

446  
 447 **Table 2:** Comparison of primary endpoints and composite primary outcomes in the short-  
 448 course and conventional duration groups

Surgical Site Infection (SSI)	Short-Course Group (N = 70) n (%)	Conventional Duration Group (N = 70) n (%)	P Value*
Superficial incisional SSI	22 (31.4)	23 (32.8)	
Deep incisional SSI	2 (2.8)	1 (1.4)	0.764
Organ space infection	2 (2.8)	1 (1.4)	
Recurrent intra- abdominal infection	4 (5.7)	2 (2.8)	

Composite primary  
outcomes 27 (37) 25 (35.7)

449 \*Chi-square test.

450

451

452 **Table 3:** Comparison of secondary outcomes in short-course and conventional duration groups

Secondary Outcomes	Short-Course Group (N = 70) (Duration in Days)	Conventional Duration Group (N = 70) (Duration in Days)	P Value*
Antimicrobial therapy	5	8 (7–10)	<0.001
Antimicrobial-free days @30 days interval	25	22 (20–23)	<0.001
Hospitalisation after index procedure	5	7(7–10)	0.014
Hospital free days @30 days' interval	25 (23–25)	23 (20–23)	0.012

453 \*Mann-Whitney U test.

454

455

456 **Table 4:** Comparison of the time till occurrence of the primary endpoints and composite  
457 primary outcomes in short-course and conventional duration groups

Time to Event	Short-Course Group N = 70 (Duration in Days)	Conventional Duration Group N = 70 (Duration in Days)	P Value*
Surgical site infections	3.8+/-0.7	4.2+/-1.2	0.77
Recurrent intra-abdominal infection	7+/-1.8	5.3+/-0.5	0.195
Composite primary outcomes	4.1+/-1.6	4.5+/-1.3	0.256

458 \*Mann-Whitney U test.

459



460 **Table 5:** Comparison of organisms of aerobic infection in short-course and conventional  
 461 duration groups

<b>Organisms of Aerobic Infection</b>	<b>Short-Course Group N = 70 (%)</b>	<b>Conventional Duration Group N = 70 (%)</b>	<b>P Value*</b>
<b>Aerobic infection</b>	34 (48.5)	39 (55.7)	0.397
<b>Anaerobic infection</b>	2 (2.8)	2 (2.8)	0.97
<b><i>E. coli</i></b>	27 (38.5)	28 (40)	0.706
<b><i>Enterococcus</i></b>	10 (14.2)	10 (14.2)	
<b><i>Klebsiella</i></b>	5 (7.1)	8 (11.4)	
<b><i>Pseudomonas</i></b>	6 (8.5)	7 (10)	
<b><i>Acinetobacter</i></b>	1 (1.4)	3 (4.2)	
<b>More than one organism</b>	11 (15.7)	14 (20)	

462 \*Fisher exact.